论文部分内容阅读
雌激素受体β(ERβ)是雌激素受体的另一亚型。众多体内外实验证明,ERβ与乳腺癌的生长有密切联系。ERβ低表达会促进乳腺癌增殖,介导转移,还能抑制乳腺癌细胞的凋亡。临床数据证明,ERβ在乳腺癌患者的癌旁组织中表达高于癌组织,且与乳腺癌患者的总生存率相关。ERβ与雌激素受体α(ERα)、表皮生长因子受体(EGFR)、孕激素受体(PR)均有密切联系:ERα和ERβm RNA平均表达水平比值(ERβ/ERα)升高,对抗癌药物有拮抗作用,反之则有协同作用;ERβ的表达量受PR调节,并能通过EGFR及下游信号通路,抑制上皮-间充质转化。临床乳腺癌样本表明,ERβ低表达可能与启动子甲基化有关。因此,采用药物调节ERβ的表达以及敏感性,是具有很大临床价值的潜在治疗手段。综述ERβ以及ERβ与相关受体之间的联系在乳腺癌生长中的作用。
Estrogen receptor β (ERβ) is another subtype of the estrogen receptor. Many in vitro and in vivo experiments show that ERβ is closely related to the growth of breast cancer. Low expression of ERβ can promote breast cancer proliferation, mediate metastasis, but also inhibit breast cancer cell apoptosis. Clinical data demonstrate that ERβ is more expressed in cancerous tissues of breast cancer patients than in cancerous tissues and is associated with overall survival in breast cancer patients. ERβ is closely related to ERα, EGFR and PR. The ERβ and ERβmRNA expression levels are increased (ERβ / ERα) Cancer drugs have antagonistic effects, and vice versa there is a synergistic effect; ERβ expression by PR regulation, and through the EGFR and downstream signaling pathway, inhibition of epithelial-mesenchymal transition. Clinical breast cancer samples show that low ERβ expression may be related to promoter methylation. Therefore, the use of drugs to regulate the expression and sensitivity of ERβ is a potential therapeutic approach with great clinical value. The role of ERβ and the relationship between ERβ and related receptors in breast cancer growth is reviewed.